Hans Den Bieman, CEO of Blue Health Vision.
Photo: Blue Health Vision.
Blue Health Vision, a biotechnology research company offering solutions designed to improve the welfare and resilience of aquatic animals throughout their production cycles, has announced it is entering a new phase of growth, expanding into new aquaculture markets, and has appointed Hans Den Bieman as its new CEO to lead that expansion.
"His appointment marks an important step in accelerating Blue Health Vision's development and expanding its impact across the sector," the company said in a statement.
With over 30 years of global experience in aquaculture, Hans Den Bieman holds a Master's degree in Aquaculture (MSc) from Wageningen University and brings deep industry knowledge and a solid track record in expanding high-performance aquaculture operations.
This expertise includes executive positions at Nutreco, where he served as COO Aquaculture for five years, and Marine Harvest (now Mowi), where he served as CEO from 2005 to 2007. In addition, he is also the owner at Sealand Aquaculture—the largest smolt producer in Chile—as well as a shareholder and member of the Supervisory Board at The Kingfish Company.
Although the company announced the appointment at the end of April, it was only yesterday that Hans Den Bieman commented on it on his LinkedIn profile. "I have taken on the role of CEO at Blue Health Vision. Blue Health Vision's unique approach, using molecular technology to strengthen resilience and improve performance in aquatic species, has great potential to shape the future of aquaculture," he wrote.
"There is a good foundation in place, with proven results in salmon and tilapia in Chile and Brazil," he continued. "Together we will accelerate the impact across the industry. We are just at the beginning of this next chapter. There is more to come, new developments, new products, and exciting results ahead," Blue Health Vision's new CEO concluded.
Part of a Dutch health consortium focused on applying a unique molecular technology to improve health and performance across animals, humans, and plants, Blue Health Vision's solutions are, as mentioned above, designed to improve the wellfare and resilience of aquatic animals throughout their production cycles.
As the biotechnology research company explains, by supporting the immune system and maintaining biological balance, its technology helps ensure that energy is directed toward growth and performance rather than being lost in stress responses.
This, the company noted, is especially relevant in modern aquaculture, where producers face increasing biological pressure, regulatory constraints, and the need for more sustainable production practices.
Thus, to validate its market potential, Blue Health Vision began commercial operations in Chile, where its headquarters are located, and Brazil. In both markets, the solutions have achieved strong adoption, delivered measurable production benefits, and generated recurring purchases, demonstrating their value to producers.
In announcing the appointment of its new CEO, the company explained that, building on this success, Blue Health Vision is expanding into new regions and preparing to enter high-value, fast-growing aquaculture markets, entering the new phase of growth he has to lead.
"With a scalable technology and a focus on resilience-driven performance, Blue Health Vision is well positioned to play a meaningful role in the future of aquaculture health management under Hans den Bieman's leadership," the company's statement concluded.